Core C, the Heart/Cell Function Core, is going to serve projects 1-3 in this Program Project Grant to fulfill the following functions: 1. To establish reliable and economical mouse myocardial infarction models by permanently or temporarily ligating the left anterior descending coronary artery. These models will be the flatform for testing the therapeutical treatments in all projects to offer proof-of-concepts for further tests in large mammal (porcine) models; 2. To study in vivo cardiac function changes after Ml injury by echocardiography (weekly) and invasive intraventricular hemodynamic measurements (at the end of each study). These measurements will offer reproducible assessments of the efficacy of all treatments; 3. To isolate and characterize cardiac myocyte function to explore the cellular mechanisms of the potential beneficial effects of the therapeutical modalities as proposed in each project. 4. To centralize tissue and cell samples (mouse and pig) for each project. In this core, we will fix or freeze tissue or isolated cell samples after the treatment is done. These samples will be collected and kept in a centralized and well-maintained facility. The samples will be distributed for each project upon request. 5. To prepare histological samples for all projects. 6. To prepare tissues for molecular analysis and perform these studies when needed. In summary. Core C will provide essential support for all projects in this Project Program Project in an economical while scientifically reliable and efficient way.
Myocardial infarction is a significant health problem with few effective therapies to slow or reverse the pathological structural and functional remodeling that it induces. This core will produce reliable mouse model systems for investigators in projects to study. This core will also prepare cells and tissues from pigs (Core B) for investigators in all 3 projects.
|Molkentin, Jeffery D (2014) Letter by Molkentin regarding article, "The absence of evidence is not evidence of absence: the pitfalls of Cre Knock-Ins in the c-Kit Locus". Circ Res 115:e21-3|
|Hullmann, Jonathan E; Grisanti, Laurel A; Makarewich, Catherine A et al. (2014) GRK5-mediated exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear NFAT activity. Circ Res 115:976-85|
|van Berlo, Jop H; Kanisicak, Onur; Maillet, Marjorie et al. (2014) c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 509:337-41|
|Scimia, Maria C; Gumpert, Anna M; Koch, Walter J (2014) Cardiovascular gene therapy for myocardial infarction. Expert Opin Biol Ther 14:183-95|
|Davis, Jennifer; Molkentin, Jeffery D (2014) Myofibroblasts: trust your heart and let fate decide. J Mol Cell Cardiol 70:9-18|
|Correll, Robert N; Eder, Petra; Burr, Adam R et al. (2014) Overexpression of the Na+/K+ ATPase ?2 but not ?1 isoform attenuates pathological cardiac hypertrophy and remodeling. Circ Res 114:249-56|
|Duran, Jason M; Makarewich, Catherine A; Trappanese, Danielle et al. (2014) Sorafenib cardiotoxicity increases mortality after myocardial infarction. Circ Res 114:1700-12|
|Barr, Larry A; Makarewich, Catherine A; Berretta, Remus M et al. (2014) Imatinib activates pathological hypertrophy by altering myocyte calcium regulation. Clin Transl Sci 7:360-7|
|Makarewich, Catherine A; Zhang, Hongyu; Davis, Jennifer et al. (2014) Transient receptor potential channels contribute to pathological structural and functional remodeling after myocardial infarction. Circ Res 115:567-80|
|Houser, Steven R (2014) Role of RyR2 phosphorylation in heart failure and arrhythmias: protein kinase A-mediated hyperphosphorylation of the ryanodine receptor at serine 2808 does not alter cardiac contractility or cause heart failure and arrhythmias. Circ Res 114:1320-7; discussion 1327|
Showing the most recent 10 out of 19 publications